94
Participants
Start Date
June 30, 2013
Primary Completion Date
December 31, 2016
Study Completion Date
April 30, 2017
Entecavir
In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
Interferon alfa-2b
In arm 2 and 3, interferon alfa-2b is used for 48 weeks
Interleukin 2
In arm 3, Interleukin 2 is used for 12 weeks
Hepatitis B Vaccine
In arm 3, Hepatitis B Vaccine is used for 48 weeks
Tongji Hospital, Wuhan
Anhui Provincial Hospital, Hefei
BeiJing YouAn Hospital, Capital Medical University, Beijing
First Hospital, Beijing University, Beijing
People'S Hospital Under Beijing University, Beijing
The First Affiliated Hospital of Fujian Medical University, Fuzhou
Department of infectious disease, Nanfang Hospital of Southern Medical University, Guangzhou
Departmen of infectious disease, Xiangya Hospital, Central-south Universit, Changsha
ShengJing Hospital of China Medical University, Shenyang
Shanghai Ruijin Hospital, Jiao Tong University School of Medicine, Shanghai
The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou
The first affiliated hospital of Wenzhou medical universtiy, Wenzhou
Collaborators (1)
Beijing Kawin Technology Share-Holding Co., Ltd.
INDUSTRY
Fujian Cosunter Pharmaceutical Co. Ltd
INDUSTRY
Tongji Hospital
OTHER